Advertisement

Psychodysleptika

  • Thomas Geschwinde

Zusammenfassung

Die Zusammenfassung psychotroper Substanzen der verschiedensten chemischen Struktur und Anwendungsformen unter Oberbegriffen erfolgt in diesem Buch in erster Linie im Hinblick auf vergleichbare durch sie ausgelöste psychische Wirkungen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abel EL (1971) Marihuana and memory: acquisition or retrieval? Science 173: 1038–1040CrossRefGoogle Scholar
  2. Abel EL (1976) The scientific study of marihuana. Hall, ChicagoGoogle Scholar
  3. Abelson PH (1968) LSD and marihuana. Science 159: 89–97Google Scholar
  4. Aberle D (1966) The Peyote religion among the Navaho. Aldine, ChicagoGoogle Scholar
  5. Ablon SL, Goodwin FK (1974) High frequency of dysphoric reactions to tetrahydrocannabinol among depressed patients. Am J Psychiatry 131: 448–453Google Scholar
  6. Abood LG, Biel JH (1962) Anticholinerge Psychotomimetica. Int Rev Neurobiol 4: 217–273CrossRefGoogle Scholar
  7. Agurell S et al. (1971) Metabolism of 7-hydroxy-delta 1 (16)-THC and CBN. Acta Pharm Suec 8Google Scholar
  8. Agurell S, Dewey WL, Willette RE (eds) (1984) The cannabinoids: chemical, pharmacologic and therapeutic aspects. Academic Press, New YorkGoogle Scholar
  9. Akinloye BA, Court WE (1981) The alkaloids of Rauwolfia volksinii. J Ethnopharmacol 4: 99–109CrossRefGoogle Scholar
  10. Alpert R (1969) Psychedelics and sexual behavior. J Sex Res 5: 50–54CrossRefGoogle Scholar
  11. Amendt G (1974) Haschisch und Sexualität. Enke, StuttgartGoogle Scholar
  12. Anderson EF (1969) The biogeography, ecology, and taxonomy of lophophora (cactacea). Brittonia 21 /4: 229–310CrossRefGoogle Scholar
  13. Andréasson S, Engström A, Allebeck P, Rydberg U (1988) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet I I: 1483–1486Google Scholar
  14. Andrews G, Vinkenoog S (eds) (1968) The book of grass. Grove, New YorkGoogle Scholar
  15. Angst J (1970) Halluzinogen-Abusus. Schweiz Med Wochenschr 100: 710–715Google Scholar
  16. Angst J, Dittrich A, Woggon B (1972) Psychologische und klinische Aspekte des Cannabismi Bbrauchs. Z Allgemeinmed 48: 94–99Google Scholar
  17. Baker AA, Lukas EG (1969) Some hospital admissions associated with cannabis. Lancet I: 148–160Google Scholar
  18. Barnes C, Fried PA (1974) Tolerance to delta-9-THC in adult rats with differential delta-9THC exposure with immature or during early adulthood. Psychopharmacology (Berlin) 34: 181–190CrossRefGoogle Scholar
  19. Battegay R, Bäumler J, Gnirss F, Ladewig D (1969) Zur Drogenabhängigkeit vom Typ Cannabis ( Haschisch, Marihuana). Schweiz Med Wochenschr 99: 965–971Google Scholar
  20. Battersby AR (1963) Recent reasearches on indole alkaloids. Pure Appl Chem 6: 471–488CrossRefGoogle Scholar
  21. Bauer W (Hrsg) (1980) Fliegenpilz — Fleisch der Götter, Schamanistische Ekstasekulte in Europa. Trikont, MünchenGoogle Scholar
  22. Baumgartner AM, Jones PF, Black CT (1981) Detection of phencyclidine in hair. J Forensic Sei 26: 576–581Google Scholar
  23. Baumgartner WA (1986) Analysis of tetrahydrocannabinol (THC) in hair. US-Navy Rehabilitation Center Study, Final Report, pp 1–16Google Scholar
  24. Beaubrun MH, Knight F (1973) Psychiatric assessment of 30 chronic users of cannabis and 30 matched controls. Am J Psychiatry 130: 309–311Google Scholar
  25. Behr H-G (oJ) Haschisch-Kochbuch. Volksverlag, LindenGoogle Scholar
  26. Behr H-G (1982) von Hanf ist die Rede. Sphinx, BaselGoogle Scholar
  27. Benitez F (1968) En la tierra mâgica del peyote. Biblioteca Era, Serie Popular, MexicoGoogle Scholar
  28. Berhardson G, Gunne LM (1972) 46 cases of psychoses in cannabis abusers. Int J Addict 7: 9–16Google Scholar
  29. Beringer K (1927) Der Meskalinrausch. Springer, Berlin (Neudruck 1969 )Google Scholar
  30. Beringer K (1932) Zur Klinik des Haschischrausches. Nervenarzt 5: 30–41Google Scholar
  31. Bialos DS (1970) Adverse marijuana reactions: A critical examination of the literature with selected case material. Am J Psychiatry 127: 819–823Google Scholar
  32. Binder MA (1981) Haschisch und Marihuana — was der Arzt über Cannabinoide wissen sollte. Dtsch Ärztebl 78: 117–120Google Scholar
  33. Bischoff WH (1966) The exstasy drugs. Univ Circle Press, Delray BeachGoogle Scholar
  34. Blaine JD, Meacham MP, Janowsky DS, Schoor M, Bozetti LP (1976) Pharmacology of marijuana. Raven, New YorkGoogle Scholar
  35. Blevins D, Regan JD (1976) Delta-9-THC: Effect on macromolecular synthesis in human and other mammalian cells. In: Nahas GG, Paton WOM, Idänpää-Heikkilä JF (eds) Marihuana: Chemistry, biochemistry, and cellular effects. Springer, New York, pp 32–68Google Scholar
  36. Boettcher C (1866) Über die Anwendung des indischen Hanfes in der Psychiatrie. Berl Klin Wochenschr 3Google Scholar
  37. Bonnie RJ, Whitebread CH (1978) The marihuana conviction. Univ Press of Virginia, CharlottesvilleGoogle Scholar
  38. Borg J, Gershon S, Alpert M (1975) Dose effects of smoked marihuana on human cognitive and motor function. Psychopharmacologia 42: 211–218CrossRefGoogle Scholar
  39. Boroffka A (1978) Cannabis und Psychiatrie. Suchtgefahren 24: 28–37Google Scholar
  40. Bost RO (1988) 3,4-Methylendioxymethamphetamine (MDMA) and other Amphetamine Derivats. J For Sci 33/2:576–587Google Scholar
  41. Bové FJ (1970) The story of Ergot. Karger, BaselGoogle Scholar
  42. Bowman M, Pihl R (1973) Cannabis: Psychiological effects of chronic heavy use. Psycho-pharmacology (Berlin) 29: 159–170Google Scholar
  43. Bram S, Bracet P (1976) Inhibition of proliferation and differentation of D. discoideum amoebae by THC and cannabinol. In: Nahas GG, Paton WOM, Idänpää-Heikkilä JF (eds) Marihuana: Chemistry, biochemistry, and cellular effects. Springer, New York, pp 116–138Google Scholar
  44. Braude MC, Szara S (eds) (1976) Pharmacology of marijuana. Raven, New York Brawley P et al. ( 1972 ) Pharmacology of hallucinogens. Pharmacol Rev. 24Google Scholar
  45. Bremkamp S (1980) PCP: Learning to like a dangerous drug. J Psychedelic Drugs 12/2:171–172Google Scholar
  46. Brickenstein R (1971) Gefahren der Cannabisdrogen für Heranwachsende. Z Allgemeinmed 47: 846–851Google Scholar
  47. Bromberg W (1934) Marihuana intoxication. Am J Psychiatry 91: 303–340Google Scholar
  48. Bron B (1979) Psychopathologisches Erscheinungsbild und klinische Bedeutung des Horror-Trips. Suchtgefahren 25 /4: 167–176Google Scholar
  49. Brown FC (1972) Halluzinogenic drugs. Thomas, Springfield/ILGoogle Scholar
  50. Brunner TF (1977) Marijuana in Ancient Greece and Rome? J Psychedelic Drugs 9 /3: 221–225CrossRefGoogle Scholar
  51. Bschor F (1950) Marihuana. Kriminalistik 4: 19–24Google Scholar
  52. Bull J (1971) Cerebral atrophy in young Cannabis smokers. Lancet II: 1420–1448Google Scholar
  53. Burroughs W, Ginsberg A (1964) Auf der Suche nach Yagé. Limes, WiesbadenGoogle Scholar
  54. Burstein S, Kupfer D (1971) Hydroxylation of trans-delta-1-THC by hepatic microsomal oxygenase. Ann. NY Acad Sci 191: 32–37Google Scholar
  55. Butler JL, Gaines LS, Lenox JR (1976) Effects of marijuana, expectation and suggestibility on cognitive functioning. Percept Mot Skills 42: 1059–1065CrossRefGoogle Scholar
  56. Bye RA Jr (1979) Hallucinogenic plants of the tarahumara. J Ethnopharmacol 1: 23–48CrossRefGoogle Scholar
  57. Caldwelle DF et al. (1969) Auditory and visuel threshold effects of marihuana in man. Percept Motor Skills 29: 755–759CrossRefGoogle Scholar
  58. Campbell AMG, Evans M, Thomson JLG, Williams MJ (1971) Cerebral atrophy in young cannabis smokers. Lancet II: 1219–1224Google Scholar
  59. Campbell AMG, Evans M, Thomson JLG, Williams MJ (1972) Cerebral atrophy in young cannabis smokers. Lancet I:202 ff.Google Scholar
  60. Carlin AS, Trupin EW (1977) The effect of long-term chronic marijuana use on neuropsychological functioning. Int J Addict 12: 36–48Google Scholar
  61. Carlin AS et al. (1972) Social facilitation of marihuana intoxication. J Abnorm Psychol 80: 132–140CrossRefGoogle Scholar
  62. Carlson KA (1979) PCP from the other side. J Psychedelic Drugs 11 /3: 231–238CrossRefGoogle Scholar
  63. Cashman J (1968) LSD, die Wunderdroge. Ullstein, Frankfurt am MainGoogle Scholar
  64. Casswell M (1975) Cannabis and temporal desintegration on experienced and naive subjects. Science 179: 803–805CrossRefGoogle Scholar
  65. Casto D (1970) Marijuana and the assassins, an etymological investigation. Br J Addict 65: 219–225CrossRefGoogle Scholar
  66. Chait LD, Fischman MW, Schuster CR (1985) “Hangover” effects the morning after marijuhana smoking. Drug Alcohol Depend 15:229–238Google Scholar
  67. Chatterjee A (1953) Rauwolfia alkaloids. Fortschr Chem Organ Naturstoffe 10: 390–394Google Scholar
  68. Cherniak L (1979) The great books of hashish. And/Or Press, BerkeleyGoogle Scholar
  69. Chiang C-W, Barnett G (1984) Marijuana effect and delta-9-tetra-hydrocannabinol plasma level. Clin Pharmacol Ther 36: 234–238CrossRefGoogle Scholar
  70. Chopra GS (1973) Studies on psycho-clinical aspects of long-term marihuana use in 124 cases. Int J Addict 8: 1015–1026Google Scholar
  71. Clark LD, Nakashima EN (1968) Experimental studies of marihuana. Am J Psychiatry 125: 379–384Google Scholar
  72. Claussen U, Korte F (1966) Herkunft, Wirkung und Synthese der Inhaltsstoffe des Haschisch. Naturwissenschaften 21: 541–546Google Scholar
  73. Co BT, Goodwin DW, Gado M, Mikhael M, Hill SY (1977) Absence of cerebral atrophy in chronic cannabis users. JAMA 237 /12: 1229–1230CrossRefGoogle Scholar
  74. Cohen S (1965) The beyond within — The LSD story. Atheneum, New YorkGoogle Scholar
  75. Cohen S (1966) A classification of LSD complications. Psychosomatics 7: 182–186Google Scholar
  76. Cohen S (1982) Cannabis and sex: Multifacted paradoxes. J Psychedelic Drugs 14/1–2: 55–58Google Scholar
  77. Colbach E (1971) Marijuana use by GI’s in Vietnam. Am J Psychiatry 128: 204–207Google Scholar
  78. Coleman JH, Tacker HL, Evans WE, Lemmi H, Britton EL (1976) Neurological manifestations of chronic marihuana intoxication, part 1: Paresis of the fourth cranial nerve. Dis Nery Syst 37: 29–38Google Scholar
  79. Consroe PF, Man DP (1973) Effects of z18- and d9-tetrahydrocannabinol on experimental induced seizures. Life Sci 13: 429–439CrossRefGoogle Scholar
  80. Cooper R (1978) A guide to British psilocybin mushrooms. Hassle Free PressGoogle Scholar
  81. Crawford WJ, Merritt JC (1979) Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm 17: 191–196Google Scholar
  82. DalCason TA (1989) The characterization of some 3,4-methylenedioxyphenylisopropylamine (MDA) analogs. J For Sci 34 /4: 928–961Google Scholar
  83. Daldrup T, Reudenbach G, Kimm K (1987) Cannabis und Alkohol im Straßenverkehr. Blutalkohol 24: 144–155Google Scholar
  84. Dalterio S, Bartke A (1979) Perinatal exposure to cannabinoids alters male reproductive function in mice. Science 205: 1420–1422CrossRefGoogle Scholar
  85. Daunderer M (1979) Therapie einer Atropa-belladonna-Vergiftung mit dem Antidot Physostigmin Med Welt 30: 1743Google Scholar
  86. Davenport J (1966) Aphrodisiacs and love stimulants. Lyle Stuart, New YorkGoogle Scholar
  87. Diaz JL (1979) Ethnopharmacology and taxonomy of Mexican psychodysleptic plants. J Psychedelic Drugs 11/1–2: 71–101Google Scholar
  88. Dieckhöfer K, Goenchea S (1972) Zur Toxizität von Cannabis. 1. Mitteilung. Med Welt 23: 779–782Google Scholar
  89. Domino EF (1981) Cannabinoids and the cholinergic system. J Clin Pharmacol [Suppl] 21:149 S-255 SGoogle Scholar
  90. Don Castro III (1970) Marihuana and the assassins. Br J Addict 65: 35–39CrossRefGoogle Scholar
  91. Doorenbos NJ et al. (1971) Cultivation, extraction and analysis of cannabis. Ann NY Acad Sci 191: 90–95CrossRefGoogle Scholar
  92. Dornbush RL, Abrams R, Fink M (1971) Marijuana, memory and perception. Am J Psychiatry 128: 194–197Google Scholar
  93. Dowling GP, McDonough ET, Bost RO (1987) „Ere“ and „Ecstasy”. A report of five deaths associated with the use of MDEA and MDMA. JAMA 257/12:1615–1617Google Scholar
  94. Eberle P (1973) Verursachen Halluzinogene Chromosomendefekte und Mißbildungen? Nervenarzt 44: 281–284Google Scholar
  95. Edery H, Soroko D, Kunberg W (1971) Structural requirements for cannabinoid activity. Ann NY Sci 191: 139–145CrossRefGoogle Scholar
  96. Efron DH (1970) Psychotomimetic drugs. Raven, New YorkGoogle Scholar
  97. Efron D, Holmstedt B, Kline NS (eds) (1967) Ethnopharmacological search for psychoactive drugs. Public Health Sery Publ 1645: 211–216Google Scholar
  98. Eliade M (1956) Schamanismus und archaische Ekstasetechnik. Rascher, Zürich StuttgartGoogle Scholar
  99. Estrada A (1980) Maria Sabina, Botin der heiligen Pilze. Trikont, MünchenGoogle Scholar
  100. Eugster CH (1968) Wirkstoffe aus dem Fliegenpilz. Naturwissenschaften 55: 305–313CrossRefGoogle Scholar
  101. Farnsworth NR (1968) Hallucinogenic plants. Science 162: 96–105CrossRefGoogle Scholar
  102. Feldman HW et al. (eds) (1979) Angel dust: An ethnographic study of PCP users. Lexington Books, Lexington/MAGoogle Scholar
  103. Feuerlein W (Hrsg) (1980) Cannabis heute, Bestandsaufnahme zum Haschischproblem. Akademische Verlagsgesellschaft, WiesbadenGoogle Scholar
  104. Fink DJ, Ashworth B, Brewer C (1972) Cerebral atrophy in young cannabis smokers. Lancet I: 143–147Google Scholar
  105. Fisher G, Steckler A (1974) Psychological effects, personality and behavioral changes attributed to marihuana use. Int J Addict 9: 101–126Google Scholar
  106. Fligiel SEG, Venkat H, Gong H, Tashkin DP (1988) Bronchial pathology in chronic marijua- na smokers: a light and electron microscopic study. J Psychoactive Drugs 20: 33–42CrossRefGoogle Scholar
  107. Franks HM, Starmer GA, Chesher GB, Jackson DM, Hensley VR, Hensley WJ (1975) The interaction of alcohol and delta-9-tetrahydrocannabinol in man. Effects on psychomotor skills related to driving. Add. Res. Fornd. of Ontario, TorontoGoogle Scholar
  108. Frederking W (1955) LSD-25 and mescaline in psychotherapy. J Ment Dis 121: 70–77Google Scholar
  109. Freedman DX (1963) Psychotomimetic drugs and brain biogenic amines. Am J Psychiatry 119: 843–850Google Scholar
  110. Fried PA (1977) Behavioral and electroencephalographic correlates of the chronic use of marihuana — a review. Bull Narc 29 /2: 29–34Google Scholar
  111. Friedberg C (1965) Des Banisteriopsis utilisés comme drogue en Amérique du sud. J Agric Trop Bot Appl 12:403–437, 550–594, 729–780Google Scholar
  112. Furst PT (1971) Ariocarpus retusus, the “false peyote” of Huichol tradition. Econ Bot 25 /1: 182–187CrossRefGoogle Scholar
  113. Furst PT (ed) (1972) Flesh of the gods: The ritual uses of hallucinogens. Prager, New York Furst PT (1976) Hallucinogens and culture. Chandler & Sharp, San FranciscoGoogle Scholar
  114. Galanter M, Wyatt R, Lemberger L, et al. (1972) Marijuana intoxication: Interaction between physiologic effects and subjective experience. Science 176: 934–936Google Scholar
  115. Gale EN, Guenther G (1971) Motivational factors associated with the use of cannabis. Br J Addict 13: 30–36Google Scholar
  116. Gaoni Y, Mechoulam R (1964) Isolation, Structure and partial synthesis of an active constituent of hashish. J Am Chem Sci 86: 136–147Google Scholar
  117. Gautier T (1846) Le club des hachichins. Revue des Deux MondesGoogle Scholar
  118. Gerlach D, Schilling S (1984) Phencyclidin, Hinweise zur Erkennung und Behandlung von PCP-Intoxikationen. Suchtgefahren 30: 273–279Google Scholar
  119. Gielsdorf W, Klug E (1981) Neues Rauschmittel auf dem Drogenmarkt: 2,5-Dimethoxy-4bromamphetamin ( DOB ). Dtsch Apoth Z 20: 1003–1005Google Scholar
  120. Gilmour DG, Bloom AD, Kusum PL, Robbins ES, Maximilian C (1971) Chromosomal aberrations in users of psychoactive drugs. Arch Gen Psychiatry 24: 268–272CrossRefGoogle Scholar
  121. Goenchea S, Dieckhöfer K (1972) Zur Toxizität von Cannabis, 2. Mitteilung. Med Welt 23: 1148–1151Google Scholar
  122. Goode E (1970) The marijuana smokers. Basic, New YorkGoogle Scholar
  123. Gorman M, Neuss N, Cone NJ (1965) Vinca alkalois, XVII. Chemistry of catharanthine. J Am Chem Soc 87: 93Google Scholar
  124. Gostomzyk JG, Parade P, Gewecke H (1973) RauschmittelgenuB und Leistungsfähigkeit ( Untersuchungen zur Energiebildung unter Haschisch ). Z Rechtsmed 73: 131–136Google Scholar
  125. Green GS (1984) Discussion of the use of marihuana, ethanol, and other drugs among drivers killed in single vehicle crashes. J Forensic Sci 29: 16–21Google Scholar
  126. Grinker RR (1964) Bootlegged ecstasy. JAMA 187: 768CrossRefGoogle Scholar
  127. Grinspoon L, Bakalar JB (1981) Psychedelic drugs reconsidered. Basic, New York Grof S ( 1983 ) LSD-Psychotherapie. Klett-Cotta, StuttgartGoogle Scholar
  128. Gröger D (1966) Fortschritte der Chemie und Biochemie der Mutterkornalkaloide. Fortschr Chem Forsch 6: 159–164CrossRefGoogle Scholar
  129. Gross D (1971) Vorkommen, Struktur und Biosynthese natürlicher Piperidinverbindungen. Fortschr Chem Org Naturstoffe 29: 1–18Google Scholar
  130. Gruenwaldt G (1971) Haschisch, Marihuana, LSD — Eigenschaften, Bedeutung, Gefahren. Saari Ärztebl 24: 33–37Google Scholar
  131. Grupp SE (1972) Multiple drug use in a sample of experienced marijuana smokers. Int J Addict 7: 481–491Google Scholar
  132. Haenel TA (1970) Kulturgeschichte und heutige Problematik des Haschischs. Pharmakopsychiat Neuropsychopharmakol 3: 89–115CrossRefGoogle Scholar
  133. Hai H (1984) Das Hanfhandbuch. Piper, Löhrbach ( Der grüne Zweig, Bd 73 )Google Scholar
  134. Halikas JA, Goodwin DW, Guze SB (1972) Marihuana use and psychiatric illness. Arch Gen Psychiatry 27: 162–165CrossRefGoogle Scholar
  135. Hallucinogenic and Psychedelic Drug Synthesis Manual (1976) Salt and Pepper Syndicate. Lawrence/KSGoogle Scholar
  136. Harding R, Knight F (1973) Marihuana-modified mania. Arch Gen Psychiatry 29: 635–637CrossRefGoogle Scholar
  137. Harner MJ (ed) (1973) Hallucinogens and shamanism. Oxford Univ Press, LondonGoogle Scholar
  138. Harvey DJ (1985) Marihuana 1984. IRL Press, OxfordGoogle Scholar
  139. Harzer K (1982) Nachweis von LSD in Körperflüssigkeiten mit Hochleistungsflüssigkeitschromatographie. J Chromatogr 249: 205–211CrossRefGoogle Scholar
  140. Hasse HE, Waldmann H (1971) „Flashback“: Spontane psychotische Episoden als Folgeerscheinung des Phantasticagebrauchs Jugendlicher. Arch Psychiatr Nervenkr 214:399–439Google Scholar
  141. Hawkes JG et al. (ed) (1979) The biology and taxonomy of the solonaceae. Academic Press, LondonGoogle Scholar
  142. Heath RG (1976) Marihuana and delta 9 tetrahydrocannabinol: Acute and chronic effects on brain function of monkeys. In: Braude MC, Szara S (eds) Pharmacology of marihuana. Raven, New York, pp 345–356Google Scholar
  143. Heath RG, Fitzjarrell AT, Garey RE, Myers WA (1979) Chronic marihuana smoking: Its effects on function and structure of the primate brain. In: Nahas GG, Paton WDM (eds) Marihuana: Biological effects. Pergamon, New York, pp 713–730Google Scholar
  144. Heim R (1967) Nouvelles investigations sur les champignons hallucinogènes. Editions des Musées Nationaux Histoire ParisGoogle Scholar
  145. Heim R, Wasson RG (1958) Les champignons hallucinogènes du Mexique. Editions des Musées Nationaux Histoire, ParisGoogle Scholar
  146. Heinemann C (1973) Nachlassende Wirkung initialer Rauscherlebnisse und Dosisteigerung beim Haschischkonsumenten. Med Klin 68: 826–830Google Scholar
  147. Helmer R, Wunder R, Zellmann K, Haesen D (1972) Experimentelle Untersuchungen zur Fahrtüchtigkeit nach Einnahme von Haschisch. Blutalkohol 4: 213–220Google Scholar
  148. Henderson GL (1988) Designer drugs, past history and future prospects. J For Sci 33 /2: 569–575Google Scholar
  149. Henderson RL, Tennant FS, Guerry R (1972) Respiratory manifestations of hashish smoking. Arch Otolaryngol 95: 248–251CrossRefGoogle Scholar
  150. Heper RS, Frank IM (1971) Marihuana smoking and intraocular pressure. JAMA 217: 1392Google Scholar
  151. Herha J (1974) Haschisch und Marihuana — eine Übersicht. Naturwissenschaften 61: 90–94CrossRefGoogle Scholar
  152. Herning RI, Jones RT, Peltzman DJ (1979) Changes in human event relate potentials with prolonged delta-9-tetrahydrocannabinol ( THC) use. Electroencephalogr Clin Neurophysiol 47: 556–570Google Scholar
  153. Hesse M (1964/1968) Indolalkaloide in Tabellen. Springer, Berlin Heidelberg New York Hesse M (1974) Progress in mass spectrometry, vol 1: Indolalkaloide. Verlag Chemie, WeinheimGoogle Scholar
  154. Hingson R, Alpert JS, Day N et al. (1982) Effects of maternal drinking and marihuana use on fetal growth and development. Pediatrics 70: 539–546Google Scholar
  155. Hirschhorn K, Cohen MM (1968) Drug-induced chromosomal aberrations. Ann NY Acad Sci 151: 977–987Google Scholar
  156. Hochman JS, Brill NQ (1973) Chronic marijuana use and psychosocial adaption. Am J Psychiatry 130: 132–139Google Scholar
  157. Hoffer A, Osmond H (1967) The hallucinogens. Academic Press, New YorkGoogle Scholar
  158. Hoffman D, Brunnemann KD, Gori GB, Wynder EL (1975) On the carcinogenicity of marihuana smoke. Res Adv Phytochem 9: 63–81CrossRefGoogle Scholar
  159. Hofmann A (1954) Die Isolierung weiterer Alkaloide aus Rauwolfia serpentina Benth. Heiv Chim Acta 37: 849–865CrossRefGoogle Scholar
  160. Hofmann A (1960 a) Psychotomimetica, eine Übersicht. Svensk Kern Tidskr 72:79–88Google Scholar
  161. Hofmann A (1960 b) Die psychotropen Wirkstoffe der mexikanischen Zauberpilze. Chimia 14:309–318Google Scholar
  162. Hofmann A (1961) Die Wirkstoffe der mexikanischen Zauberdroge Ololiuqui. Planta Med 9: 354–367CrossRefGoogle Scholar
  163. Hofman A (1964) Die Mutterkornalkaloide. Enke, StuttgartGoogle Scholar
  164. Hofmann A (1967) Psychoaktive Stoffe der Pflanzen. Therapiewoche 35: 40–47Google Scholar
  165. Hofmann A (1979) LSD — mein Sorgenkind. Klett-Cotta, StuttgartGoogle Scholar
  166. Hofmann A (1981) LSD ist eine sakrale Droge (Interview mit Dr. Hofmann). Psychol Heute 4: 55–61Google Scholar
  167. Hofmann A, Tscherter H (1960) Isolierung von Lysergsäurealkaloiden aus der mexikanischen Zauberdroge Ololiuqui. Experimentia XVI /9Google Scholar
  168. Hole G (1967) LSD und verwandte Halluzinogene. Geschichte — Wirkung — Gebrauch und Gefahren. MMW 109: 1389–1397Google Scholar
  169. Hollister LE (1968) Chemical psychoses. LSD and related drugs. Thomas, Springfield/ILGoogle Scholar
  170. Hollister LE, Richards RK, Gillespie HK (1968) Comparison of tetrahydrocannabinol and synhexyl in man. Clin Pharmacol Ther 9: 783–791Google Scholar
  171. Honecker HC, Coper C (1970) Dünnschichtchromatographische Nachweismethode von Opium als Beimengung in Haschisch-Proben. Dtsch Med Wochenschr 42: 441–443Google Scholar
  172. Huxley A (1972) The doors of perception. (dtsch. Übers: Die Pforten der Wahrnehmung. Piper, München )Google Scholar
  173. Isbell H, Gorodetzky CW, Jasinsky D, Claussen U, Spulak F, Korte F (1967) Effects of (—)-delta-9-transtetrahydrocannabinol in man. Psychopharmacologia (Berlin) 11: 184–188CrossRefGoogle Scholar
  174. Jacobson CB, Berlin CM (1972) Possible reproductive detriment in LSD users. JAMA 222:1367–1373Google Scholar
  175. Jakubovic A, McGeer D (1972) Inhibition of rat brain protein by cannabinoids in vitro. Can J Biochem 50: 654–660CrossRefGoogle Scholar
  176. Janowsky DS, Meacham MP, Blaine JD, Schoor M, Bozetti LP (1976) Simulated flying performance after marihuana intoxication. Aviat Space Environ Med 47: 124–128Google Scholar
  177. Johnson S, Domino EF (1971) Some cardiovascular effects of marihuana smoking in normal volunteers. Therapeutics 12: 762–768Google Scholar
  178. Jones H, Jones HC (1977) Sensual drugs. Cambridge Univ Press, Cambridge Jones HC, Lovinger PW ( 1985 ) The marijuana question. Mead, New YorkGoogle Scholar
  179. Jones R (1977) Human effects. NIDA Res Monogr 14: 128–178Google Scholar
  180. Joyce CRB, Curry SH (1970) The botany and chemistry of cannabis. Churchill, LondonGoogle Scholar
  181. Kaiser C, Gold R (1974) Perception, psychedelics and social change. J Psychedelic Drugs 6: 30–35CrossRefGoogle Scholar
  182. Kaplan HS (1971) Psychosis associates with marijuana. NY State J Med 71: 433–435Google Scholar
  183. Karler R (1977) Toxicological and pharmacological effects. NIDA Res Monogr 14: 55–66Google Scholar
  184. Karler R, Cely W, Turkanis SA (1974 a) Anticonvulsant properties of 4 9 -tetrahydrocannabinol and other cannabinoids. Life Sci 15: 931–947Google Scholar
  185. Karler R, Cely W, Turkanis SA (1974b) A study of the development of tolerance to an anticonvulsant effect of delta-9-THC and cannabidiol. Res Commun Chem Pathol Pharmacol 9: 23–29Google Scholar
  186. Kaymakcalan S (1975) Potential dangers of cannabis. Int J Addict 10: 721–735Google Scholar
  187. Keller K, Stahl E (1982) Kalmus: Inhaltsstoffe und Asarongehalt bei verschiedenen Herkünften. Dtsch Apoth Z 122 /48: 2463–2466Google Scholar
  188. Kennedy AB, Rätsch C (1985) Datura: Aphrodisiac? High Frontiers, BerkeleyGoogle Scholar
  189. Keup W (1967) Psychotic symptoms due to cannabis abuse (a survey of newly admitted mental patients). Dis Nerv Syst 31: 119–126Google Scholar
  190. Kielholz P, Hobi V, Ladewig D, Miest P, Richter R (1973) An experimental investigation about the effect of cannabis on car absorption. Pharmakopsychiatry 6: 91–103CrossRefGoogle Scholar
  191. Klonoff H (1983) Acute psychological effects of marihuana in man, including acute cognitive, psychomotor, and perceptual effects on driving. In: Fehr O’Brien K, Kalant H (eds) Cannabis and health hazards. Addiction Research Foundation, Toronto, pp 88–96Google Scholar
  192. Klonoff H, Low MD (1974) Psychological and neurophysiological effects of marihuana in man- An interaction model. In: Miller LL (ed) Marihuana: Effects on human behavior. Academic Press, New York, pp 359–397Google Scholar
  193. Knecht S (1962) Magische Pilze. Über die mexikanische Pilzzeremonie. Med Welt 35: 1853–1859Google Scholar
  194. Koch CAL (1864) Der Hanf. Allg Z Psychiatr 21: 13–19Google Scholar
  195. Kolansky H, Moore WT (1971) Effects of marihuana on adolescents and young adults. JAMA 216: 486–492CrossRefGoogle Scholar
  196. Konzett H (1981) Halluzinogene: LSD, Psilocybin und Mescalin. Dtsch Ärztebl 78: 283–288Google Scholar
  197. Korte F et al. (1965) THC-Carbonsäure, ein neuer Haschisch-Inhaltsstoff. Angew Chem 77Google Scholar
  198. Krumsick L (1975) Haschischöl. Kriminalistik 3: 124–128Google Scholar
  199. Kuehne ME (1964) The total synthesis of vincamine. J Am Chem Soc 86: 2946–2973CrossRefGoogle Scholar
  200. Kuehnle J, Mendelson JH, Davis DR, New PFJ (1977) Computed tomographic examination of heavy marihuana smokers. JAMA 237 /12: 1231–1232CrossRefGoogle Scholar
  201. Kumar S, Kunwar KB (1972) Chromosome abnormalities in cannabis addicts. J Assoc Phys India 19: 193–195Google Scholar
  202. Kutney JP, Brown RT, Piers E (1966) The absolute configuration of the Iboga alkaloids. Can J Chem 44: 637–645CrossRefGoogle Scholar
  203. Kvalseth TO (1977) Effects of marijuana on human reaction time and motor control. Percept Mot Skills 45: 935–939CrossRefGoogle Scholar
  204. LaBarre W (1960) Twenty years of peyote studies. Curr Anthropol 1: 45–60CrossRefGoogle Scholar
  205. LaBarre W (1972) Hallucinogens and the shamanic origins of religion. In: Furst PT (ed) Flesh of the Gods: The ritual usees of hallucinogens. Praeger, New York, pp 36–49Google Scholar
  206. La Valle S (1984) Hashish. Quarter Books, London New York MelbourneGoogle Scholar
  207. Leaf RC, De Bold RC (1967) LSD, man and society. Wesleyan Univ Press, ConnecticutGoogle Scholar
  208. Leary T (1962) How to change behaviour. (Proceedings of X IV. International Congress on Applied Psychology, Copenhagen )Google Scholar
  209. Leary T (1964) The religious experience. Psychedelic Rev 3: 30–42Google Scholar
  210. Leary T (1970) Politik der Ekstase. Wegner, HamburgGoogle Scholar
  211. Leistenfels H von (oJ) Pilze: Speisepilz-Zucht Rauschpilz-Erkennung. Pieper & Die Grüne Kraft, Löhrbach (Grüner Zweig, Bd 65)Google Scholar
  212. Leonhardt RW (1970) Haschischreport. Piper, MünchenGoogle Scholar
  213. Leuenburger H (1969) Zauberdrogen. Goverts, StuttgartGoogle Scholar
  214. Leuner H (1971) Halluzinogene in der Psychotherapie. Pharmakopsychiatry 4: 333–351CrossRefGoogle Scholar
  215. Leuner H (1981) Halluzinogene. Huber, BernGoogle Scholar
  216. Levy JA, Munson AE, Harris LS, Dewey WL (1975) Effects of delta-9-THC on the immune response of mice. Fed Proc 34: 782–789Google Scholar
  217. Lewin L ( 1927, 1981 ) Phantastica — Die betäubenden und erregenden Genußmittel. Volksverlag, LindenGoogle Scholar
  218. Lewin L (1929) Banisteria Caapi. Stilke, BerlinGoogle Scholar
  219. Lewis EG, Peters BA, Dustman RE, Straight RC, Beck EC (1976) Sensory, perceptual, motor and cognitive functioning and subjective reports following oral administration of delta-9-THC. Psychopharmacologia (Berlin) 47: 141–148CrossRefGoogle Scholar
  220. Lidz T, Rothenberg A (1970) Psychedelismus: Die Wiedergeburt des Dionysos. Psyche 24: 359–374Google Scholar
  221. Lockwood TE (1979) The ethnobotany of brugmansia. J Ethnopharmacol 1: 147–164CrossRefGoogle Scholar
  222. Ludlow FH (1981) Der Haschisch-Esser. Sphinx, BaselGoogle Scholar
  223. Madsen W (1955) Shamanism in Mexico. Southwest J Anthropol 2 /1: 48–57Google Scholar
  224. Manno JE, Kiplinger GF, Haine SE, Bennett IF, Forney RB (1970) Comparative effects of smoking marihuana or placebo on human motor and mental performance Clin Pharmacol Ther 11: 808–815Google Scholar
  225. Margolis JS, Clorfene R (1979) Der Grassgarten. Volksverlag, LindenGoogle Scholar
  226. Marijuana and Health (1980) 8th Annual Report to the US Congress from the Secretary of Health, Education and Welfare, Washington/DCGoogle Scholar
  227. Marijuana and Health (1985) Report of a study be the committee of the Institute of Medicine. National Academic Press, Washington/DCGoogle Scholar
  228. Marzell H (1964) Zauberpflanzen — Hexengetränke. Kosmos 241: 47–55Google Scholar
  229. Mason AP, McBay AJ (1984) Ethanol, marijuana, and other drugs use in 600 drivers killed in single-vehicle crashes in North Carolina, 1978–1981. J Forensic Sci 29: 987–1026Google Scholar
  230. Mason AP, McBay AJ (1985) Cannabis: Pharmacology and interpretation of effects. J Forensic Sci 30: 615–631Google Scholar
  231. McBay AJ (1985) Marijuana testing and litigation. J Forensic Sci 30: 987–994Google Scholar
  232. McGlothlin WS, Cohen S, McGlothlin M (1964) Short-term effects of LSD on anxiety, attitudes and performance. J Nery Ment Dis 139: 266–273CrossRefGoogle Scholar
  233. McGlothlin WS, Cohen S, McGlothlin M (1970) Long lasting effects of LSD on normals. J Psychedelic Drugs 3: 20–31CrossRefGoogle Scholar
  234. McLeary JA, Sypherd PS, Walkington DL (1960) Antibiotic activity of an extract of peyote Lophophora williamsii ( Lemaire) Coulter. Econ Bot 14: 247–249Google Scholar
  235. Mechoulam R (1970) Marihuana chemistry. Science 168: 1159–1166CrossRefGoogle Scholar
  236. Mechoulam R (1973) Marihuana- Chemistry, pharmacology, metabolism and clinical effects. Academic Press, LondonGoogle Scholar
  237. Mechoulam R, Gaoni Y (1965) A total synthesis of d,l -delta-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 87: 3273–3275CrossRefGoogle Scholar
  238. Meck B (1981) Die Assassinen. Econ, Düsseldorf WienGoogle Scholar
  239. Melges FT, Tinklenberg JR, Hollister LE, Gillespie HK (1970) Marihuana and temporal disintegration. Science 6: 1118–1120CrossRefGoogle Scholar
  240. Mendelson JH (ed) (1974) The use of marihuana. Plenum, New YorkGoogle Scholar
  241. Mendelson JH (1987) Marijuana. In: Meltzer HY (ed) Psychopharmacology. Raven, New York, pp 60–67Google Scholar
  242. Mendelson JH, Rossi AM, Meyer RE (eds) (1974) The use of marihuana; a psychological and physiological inquiry. Plenum, New YorkGoogle Scholar
  243. Merkus F et al. (1971) TLC, GLC and MS of cannabidivarin, tetrahydrocannabivarin and cannabivarin. Acta Pharm Suec 8Google Scholar
  244. Miller LL (ed) (1974) Marijuana — effects on human behavior. Academic Press New York San Fransisco LondonGoogle Scholar
  245. Miller RA (1983) The magical and ritual use of herbs. Destiny, New YorkGoogle Scholar
  246. Morton JF (1981) Atlas of medical plants of middel america. Thomas, Springfield/ILGoogle Scholar
  247. Moskowitz H, McGlothlin WS (1974) Effects of marihuana on auditory signal detection. Psychopharmacologia (Berlin) 48: 159–163Google Scholar
  248. Myerhoff BG (1980) Der Peyote Kult. Trikont, MünchenGoogle Scholar
  249. Nahas GG (1972) Toxicology and pharmacology of cannabis sativa with special reference to delta-9-THC. Bull Narc 24: 11–27Google Scholar
  250. Nahas GG (1974) Effects of cannabis and cannabinoids on cell replication and replication and DNA synthesis in man. J Pharmacol 5: 71–78Google Scholar
  251. Nahas GG (1979) Keep off the grass. Pergamon, Oxford New YorkGoogle Scholar
  252. Nahas GG (1982) Hashish in Islam, 9th to 18th century. Bull NY Acad Med 58 /9: 814–831Google Scholar
  253. Nahas GG (ed) (1984) Marihuana in science and medicine. Raven, New YorkGoogle Scholar
  254. Nahas GG (1986) Cannabis: toxicological properties and epidemiological aspects. Med J Aust 145: 82–87Google Scholar
  255. Nahas GG, Patton WDM (eds) (1979) Marihuana: Biological effects — analysis, metabolism, cellular responses, reproduction and brain. Pergamon, OxfordGoogle Scholar
  256. Nahas GG, Sucia-Foca N, Armand J-P, Morishima A (1974) Inhibition of cellular mediated immunity in marihuana smokers. Science 183: 419–420CrossRefGoogle Scholar
  257. Nahas GG, Desoize B, Hsu J, Morishima A, Srinivasan PR ( 1975 a) Inhibition of nucleic acid and proteins synthesis by natural cannabinoids and olivetol. (Abstract IV. Int. Congress of Pharmacology, Helsinki, p 495 )Google Scholar
  258. Nahas GG, Desoize B, Hso J, Morishima A, Srinivasan PR ( 1975 b) Inhibition of nucleic acid and proteins synthesis by natural cannabinoids and olivetol. (Abstract V I. Int. Congress of Pharmacology, Helsinki )Google Scholar
  259. Nahas GG, Paton WDM, Idänpään-Heikkilä JE (eds) (1976) Marihuana: chemistry, biochemistry and cellular effects. Springer, New YorkGoogle Scholar
  260. Negrete JC (1973) Psychological adverse effects of cannabis smoking: A tentative classification. Can Med Assoc J 108: 195–196Google Scholar
  261. Neu RL, Powes HO, King S, Gardner LI (1969) Cannabis and chromosomes. Lancet I: 675Google Scholar
  262. Neumeyer JL, Shagoury L (1971) Chemistry and pharmacology of marijuana. J Pharm Sci 60:1433–1451Google Scholar
  263. Nichols WW, Miller RC, Heneen W, Bradt C, Hollister L, Kanter S (1974) Cytogenetic studies on human subjects receiving marihuana and delta-9-tetrahydrocannabinol. Mutat Res 26: 413–417CrossRefGoogle Scholar
  264. Novotny M, Lee MC, Keast D (1976) A possible chemical basis for the higher mutagenicity of marihuana smoke as compared to tobacco smoke. Experientia 32: 280–282CrossRefGoogle Scholar
  265. Nowlan R, Cohen S (1977) Tolerance to marihuana: heart rate and subjective “high”. Clin Pharmacol Ther 22: 550–555Google Scholar
  266. Ohlsson A, Lindgren JE, Wahlen A et al. (1980) Plasma delta-9-tetrahydrocannabinol concentrations and clinic effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28: 409–416CrossRefGoogle Scholar
  267. Olvedi U (1972) LSD-Report. Suhrkamp, Frankfurt am MainGoogle Scholar
  268. Orzechowski G (1969) Halluzinogene Drogen. Med Welt 16: 955–963Google Scholar
  269. Oss OT, Oeric ON (1976) Psilocybin, magic mushrooms grower’s guide. And/Or Press, BerkeleyGoogle Scholar
  270. Ott J (1976) Hallucinogenic plants of North America. Wingbow, Berkeley/CAGoogle Scholar
  271. Ott J, Bigwood J (ed) (1978) Teonanacatl: Hallucinogenic mushrooms of North America. Madrona, Seattle/WAGoogle Scholar
  272. Pace HD, Davis A, Borgen LA (1971) Teratogenesia and marihuana. Ann NY Acid Sci 191: 123–128CrossRefGoogle Scholar
  273. Pahnke W (1963) Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness. Master’s thesis Univ of HarvardGoogle Scholar
  274. Petersen BH, Graham J, Lemberger L (1976) Marihuana, tetrahydrocannabinol and T-cell function. Life Sci 19: 395–400CrossRefGoogle Scholar
  275. Petersen RC (ed) (1977) Marihuana research findings. NIDA Res Monogr 14: 205–218Google Scholar
  276. Petersen RC (ed) (1980) Marijuana research findings. NIDA Res Monogr 31: 69–85Google Scholar
  277. Petersen RC, Stillman RC (1978) Phencyclidine ( PCP) abuse: An appraisal. NIDA Res Monogr 21: 168–175Google Scholar
  278. Petrzilka T, Haefliger W, Sikemeier G, Ohloff G, Eschenmoser A (1967) Synthese und Chiralität des (—)-Cannabidiols. Helv Chim Acta 50: 719–723CrossRefGoogle Scholar
  279. Peuckert W-E (1960) Hexensalben. Med Monatsspiegel 9: 169–174Google Scholar
  280. Pope HG Jr (1969) Tabernanthe iboga — an African narcotic plant of social importance. Econ. Bot 23: 174–184CrossRefGoogle Scholar
  281. Raffauf RF, Flagler MB (1960) Alkaloids of the apocynaceae. Econ Bot 14: 37–46CrossRefGoogle Scholar
  282. Ranke-Graves R von (1985) Griechische Mythologie. Rowohlt, ReinbekGoogle Scholar
  283. Ray R, Prabhu GG, Mohan D, Nath LM, Neki JS (1978) Cannabis use. The association between chronic cannabis abuse and cognitive functions. Drug Alcohol Dep 3: 365–368Google Scholar
  284. Rayner R (1979) Pilze erkennen — leicht gemacht. Franckh’sche Verlagshandlung, Stuttgart Reed A, Kane W (1972) Phencyclidine (PCP). J Psychedelic Drugs 5 /1: 8–12CrossRefGoogle Scholar
  285. Reeve VC, Grant JD, Robertson W et al. (1983 a) Plasma concentration of delta-9-tetrahydrocannabinol and impaired motor function. Drug Alcohol Dep 11: 167–175Google Scholar
  286. Reeve VC, Robertson WB, Grant J et al. (1983b) Hemolyzed blood and serum levels of 49-THC: Effects on the performance of roadside sobriety tests. J Forensic Sci 28: 963–971Google Scholar
  287. Remschmidt H (1972) Haschisch und LSD. Physische und psychische Wirkungen. Med Klin 67:706–716, 781–786Google Scholar
  288. Renault PF, Schuster CR, Heinrich R, Freeman DX (1971) Marihuana: Standartized smoke administration and dose effects surves on heart rate in humans. Science 174: 589–591Google Scholar
  289. Ricklin F (1989) Cannabis: harmloses Rauschgift? Schweiz Med Wochenschr 119:1173–1176Google Scholar
  290. Rivier L, Lindgren J-E (1972) Ayahuasca — South American hallucinogenic drink: ethnobotanical and chemical investigations. Econ Bot 24: 100–129Google Scholar
  291. Rodin E, Domino E, Porzak J (1970) The marijuana induced social high — Neurological and electroencephalographic concomitants. JAMA 213: 1300–1302CrossRefGoogle Scholar
  292. Rosenthal E (1984) Marijuana beer. And/Or Press, BerkeleyGoogle Scholar
  293. Safford WE (1916) Identity of cohoba, the narcotic snuff of ancient Haiti. J Wash Acad Sci 6: 548–562Google Scholar
  294. Sahihi A (1989) Designer-Drogen: die neue Gefahr. Beltz, Weinheim BaselGoogle Scholar
  295. Sallan SE, Zinberg NE, Frei E (1975) Antimetic effect of delta-9-THC in patients receiving cancer chemotherapy. N Engl J Med 293: 795–797CrossRefGoogle Scholar
  296. Sankar DVS (1975) LSD — A total study. PJD Publications, Westbury/NYGoogle Scholar
  297. Sankar DVS, Roszy PW, Geisler A (1969) Chromosome breakage in childern treated with LSD-25 and UML-491. Compr Psychiatry 10: 406–410CrossRefGoogle Scholar
  298. Saxton JE (1956) The indole alkaloids excluding harmine and strychnine. Q Rev 10: 108–112CrossRefGoogle Scholar
  299. Schleifer H (1973) Sacred narcotic plants of the New World Indians. Hafner, New YorkGoogle Scholar
  300. Schmiechen R et al. (1986) Carbolines — A new class of compounds with high affinity for benzodiazepine receptors. (Sonderdruck: IXth International Symposium on Medicinal Chemistry, Berlin )Google Scholar
  301. Schönhofer PS (1973) Die Pharmakologie der Cannabis-Wirkstoffe. Arzneimittelforsch 23: 50–55Google Scholar
  302. Schultes RE (1941) A contribution to our knowledge of rivea corymbosa, the narcotic ololiuqui of the Aztecs. Harvard Botanical Museum, Cambridge/MAGoogle Scholar
  303. Schultes RE (1969) Hallucinogens of plant origin. Science 163: 245–254CrossRefGoogle Scholar
  304. Schultes RE (1969/1970) The plant kingdom and hallucinogens. Bull Narc 21: 3–16, 22: 2553Google Scholar
  305. Schultes RE (1970 a) The botanical and chemical distribution of hallucinogens. Ann Rev Plant Physiol 21:571–590Google Scholar
  306. Schultes RE ( 1970 b) Botany and chemistry of cannabis. Churchill, LondonGoogle Scholar
  307. Schultes RE (1972) An overview of hallucinogens in the western hemisphere. In: Furst PT (ed) Flesh of the Gods: The ritual uses of hallucinogens. Praeger, New York, pp 3–54Google Scholar
  308. Schultes RE (1976) Hallucinogenic plants. Golden Press, New YorkGoogle Scholar
  309. Schultes RE, Hofmann A ( 1980 a) The botany and chemistry of hallucinogens. Thomas, Springfield/ILGoogle Scholar
  310. Schultes RE, Hofman A ( 1980 b) Pflanzen der Götter. Die magischen Kräfte der Rausch-und Giftgewächse. Hallwag, Bern StuttgartGoogle Scholar
  311. Schultz 0E, Haffner C (1958) Zur Kenntnis eines sedativen Wirkstoffes aus dem deutschen Faserhanf. Arch Pharm (Berlin) 291: 20–24CrossRefGoogle Scholar
  312. Schurz J (1970) Vom Bilsenkraut zum LSD. Franksche Verlagshandlung, StuttgartGoogle Scholar
  313. Schwarz CJ (1968) The complications of LSD: a review of the literature. J Nerv Ment Dis 146: 174–186CrossRefGoogle Scholar
  314. Sharma S, Moskowitz H (1972) Effect of marihuana on the visual autokinetic phenomenon. Percept Mot Skills 35: 891–894CrossRefGoogle Scholar
  315. Silverman J (1968) Shamans and acute schizophrenia. Am Anthropol 69: 21–31CrossRefGoogle Scholar
  316. Smith MV (1981) Psychedelic chemistry. Loompanics Unlimited Mason/USA (Nachdruck des 1973 in Rip Off Press erschienenen Werkes)Google Scholar
  317. Soueif MI (1976) Differential association between chronic cannabis use and brain function deficits. Ann NY Acad Sci 282: 323–343CrossRefGoogle Scholar
  318. Stafford P (1980) Enzyklopädie der psychedelischen Drogen. Volksverlag, Linden Stahl E et al. ( 1978 ) Rauschgiftpilze mit LSD. Arch Krim, S 162Google Scholar
  319. Stanton MD, Mintz J, Franklin RM (1976) Drug flashbacks. II. Some additional findings. Int J Addict 11: 53–69Google Scholar
  320. Starks M (1979) Marijuana potency. And/Or Press, BerkeleyGoogle Scholar
  321. Steckel R (oJ) Bewußtseinserweiternde Drogen. Haschisch-Marihuana-LSD-MeskalinSTP(DOM)-Psilocybin-Ololiuqui. Edition VoltaireGoogle Scholar
  322. Stefanis C, Dornbush R, Fink M (1977) Hashish-studies of long-term use. Raven, New YorkGoogle Scholar
  323. Stenchever MA, Kunysz TJ, Allen MA (1974) Chromosome breakage in users of marihuana. Am J Obstet Gynecol 118: 106–113Google Scholar
  324. Stoll WA (1947) Lysergsäureamid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neurol Psychiatr 60: 279–323Google Scholar
  325. Stoll WA (1952) Recent investigations on ergot alkaloids. Fortschr Chem Org Naturst 9: 114119Google Scholar
  326. Stowe BB (1959) Occurence and metabolism of simple indoles in plants. Fortschr Chem Org Naturst 17: 248–252Google Scholar
  327. Stringaris MG (1972) Die Haschischsucht. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  328. Stromberg VL (1954) The isolation of bufotenin from Piptadenia peregrina. J Am Chem Soc 76: 170–171CrossRefGoogle Scholar
  329. Svrcek M (1979) Der Kosmos-Pilzführer. Franckh’sche Verlagshandlung, Stuttgart Täschner K-L (1980) Haschisch für alle. Hess. Ärztebl 7 (Sonderdruck)Google Scholar
  330. Täschner K-L (1981) Das Haschischproblem aus klinischer Sicht. Dtsch Ärztebl 78: 126–129Google Scholar
  331. Täschner K-L (1983) Zur Psychopathologie und Differentialdiagnose sogenannter Cannabispsychosen. Fortschr Neurol Psychiatr 51: 235–248CrossRefGoogle Scholar
  332. Täschner K-L (1986) Das Cannabisproblem — Haschisch und seine Wirkungen. Deutscher Ärzteverlag, KölnGoogle Scholar
  333. Täschner K-L, FrieBem DH (1989) Verkehrstauglichkeit bei Rauschgiftkonsumenten unter besonderer Berücksichtigung des CannabismiBbrauchs. Suchtgefahren 35:253–262 (Sonderdruck)Google Scholar
  334. Täschner K-L, Wanke K (1975) Zur Frage der toxischen Psychose am Beispiel der sog. LSD-Psychose. Fortschr Med 31: 1515–1518, 1542Google Scholar
  335. Tarshis MS (1972) The LSD controversy — an overview. Thomas, Springfield/ILGoogle Scholar
  336. Tashkin DP, Simmons M, Clark V (1988) Effect of habitual smoking of marijuana alone and with tobacco on nonspecific airways hyperreactivity. J Psychoactive Drugs 20: 21–25CrossRefGoogle Scholar
  337. Taylor FM (1988) Marijuana as a potential respiratory tract carcinogen: a retrospective analysis of a community hospital population. South Med J 81: 1213–1216CrossRefGoogle Scholar
  338. Taylor WI (1966) Indole alkaloids, an introduction to the enamine chemistry of natural products. Pergamon, New YorkGoogle Scholar
  339. Tennant FS, Groesbeck CT (1972) Psychiatric effects of Hashish. Arch Gen Psychiatry 27: 133–136CrossRefGoogle Scholar
  340. Tennant FS, Preble M, Prendergast TJ, Ventry P (1971) Medical manifestations associated with Hashish. JAMA 216: 1965–1969CrossRefGoogle Scholar
  341. Thomas WR, Holt PG, Keast D (1974) Recovery of immune system after cigarette smoking. Nature 248: 358–359CrossRefGoogle Scholar
  342. Treffert DA (1978) Marihuana use in schizophrenia: a clear hazard. Am J Psychiatry 135: 1213–1215Google Scholar
  343. Ungerleider JT et al. (1968) The “bad trip” — the etiology of the adverse LSD reaction. Am J Psychiatry 124: 1483–1490Google Scholar
  344. Vierth G (1967) Psycho-pathologische Syndrome nach HaschischgenuB. MMW 1: 522–528Google Scholar
  345. Vogel R, Matthiessen W, Bruckner O, Alexander M (1981) Lungenkomplikationen bei Rauschgiftsucht. Prax Pneumol 35:988–991Google Scholar
  346. Völger G (Hrsg) (1982) Rausch und Realität, Drogen im Kulturvergleich, Bd 1–3. Rowohlt, Reinbek (Materialienband zur Ausstellung des Rautenstrauch-Joest-Museums für Völkerkunde der Stadt Köln 1981, Teil 1 und 2 )Google Scholar
  347. Waser P (1971) Pharmakologische Wirkungsspektren von Halluzinogenen. Bull Schweiz Akad Med Wiss 27: 39–57Google Scholar
  348. Wasson RG (1959) The hallucinogenic mushrooms of Mexiko. Academy of Science, New YorkGoogle Scholar
  349. Wasson RG (1962) The hallucinogenic mushrooms of Mexiko and psilocybin: a bibliography. Bot Mus Leafl Hary Univ 20: 20–73Google Scholar
  350. Wasson RG (1968) Soma. Divine mushroom of immortality. Harcourt Brace Jovanovich New YorkGoogle Scholar
  351. Wasson VP, Wasson RG (1957) Mushrooms, Russia and history. Pantheon, New YorkGoogle Scholar
  352. Wasson RG, Hofman A, Ruck CAP (1978) The road to Eleusis: Unveiling the secrets of the mysteries. Harcourt Brace Jovanovich, New YorkGoogle Scholar
  353. Wax RH, Wax ML (1962) The magical world view. J Sci Study Rel 1: 179–188CrossRefGoogle Scholar
  354. Wells B (1974) Psychedelic drugs. Penguin, BaltimoreGoogle Scholar
  355. Whites SC, Brin SC, Janicki BW (1975) Mitogen-induced blastogenic responses of lymphocytes from marihuana smokers. Science 188: 71–72CrossRefGoogle Scholar
  356. Williams EG, Himmelsbach CK, Wikler A, Ruble DC, Lloyd BJ Jr (1946) Studies on marijuana and parahexyl compound. Public Health Rep 61: 1059–1083CrossRefGoogle Scholar
  357. Winterfeldt E (1971) Neuere Aspekte in der Chemie der Indolalkaloide. Chimia 25: 394–396Google Scholar
  358. Winterfeldt E (1974) Stereoselektive Totalsynthese von Indolalkaloiden. Fortschr Chem Org Naturst 31: 469–472CrossRefGoogle Scholar
  359. Woggon B (1974) Haschisch — Konsum und Wirkung. Springer, Berlin Heidelberg New York Yago KB, Pitts FN Jr., Burgoyne RW et al. (1981) The urban epidemic of phencyclidine (PCP) use. J Clin Psychiatry 42:193–196Google Scholar
  360. Zellweger H, McDonald JS, Abbo G (1967) Is isoergicacid diethylamide a teratogen? Lancet 7525: 1066–1068CrossRefGoogle Scholar
  361. Zimmermann AM, Raj AY (1980) Influence of cannabinoids on somatic cells in vivo. Pharmacology 21: 277–287Google Scholar
  362. Zimmerman S, Zimmerman AM, Cameron IL, Laurence HL (1977) Delta-9-tetrahydrocannabinol, cannabidiol, and cannabinol effects on the immune response of mice. Pharmacology 15: 10–23CrossRefGoogle Scholar
  363. Zschockelt A (1986) Die „nicht geringe Menge“ Cannabis — Problematik der THC-Bestimmung. MDR 6: 457–459Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Thomas Geschwinde
    • 1
  1. 1.HanauDeutschland

Personalised recommendations